Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7.82M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
3.39M
-
Shares change
-
-1.59M
-
Total reported value, excl. options
-
$9.93M
-
Value change
-
-$3.96M
-
Put/Call ratio
-
1.25
-
Number of buys
-
15
-
Number of sells
-
-9
-
Price
-
$2.93
Significant Holders of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) as of Q4 2022
37 filings reported holding PMCB - PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value as of Q4 2022.
PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.39M shares
of 7.82M outstanding shares and own 43.35% of the company stock.
Largest 10 shareholders include Ayrton Capital LLC (1.03M shares), K2 PRINCIPAL FUND, L.P. (732K shares), VANGUARD GROUP INC (655K shares), EQUITEC PROPRIETARY MARKETS, LLC (331K shares), GEODE CAPITAL MANAGEMENT, LLC (175K shares), SABBY MANAGEMENT, LLC (98K shares), SIMPLEX TRADING, LLC (63.6K shares), STATE STREET CORP (62.6K shares), IQ EQ FUND MANAGEMENT (IRELAND) Ltd (40.8K shares), and NORTHERN TRUST CORP (37.6K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.